SHORT MINI-FUTURE - MODERNA | Market Closed - Deutsche Boerse AG 19:02:29 14/06/2024 BST | ||
| 4.16 EUR | +20.93% |
|
| Current month | +8.33% | ||
| 1 month | -20.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 4.16 | +20.93% |
| 13/06/24 | 3.44 | +9.90% |
| 12/06/24 | 3.13 | -4.57% |
| 11/06/24 | 3.28 | -0.30% |
| 10/06/24 | 3.29 | +7.17% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 07:02 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU3P7T |
| ISIN | DE000VU3P7T3 |
| Date issued | 17/02/2023 |
| Strike | 183 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.78 € |
|---|---|
| Lowest since issue | 1.13 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- Certificat